Categories for Press Releases

AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical 

 IRVINE, Calif., February 10, 2023 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple…

AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million

IRVINE, Calif., January 10, 2023 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple…

AEON Biopharma and Priveterra Acquisition Corp. Announce Filing of S-4 Registration Statement for Proposed Business Combination

IRVINE, Calif., December 27, 2022 – AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions,…

AEON Biopharma Completes Enrollment in Phase 2 Trial 

of ABP-450 for Preventive Treatment of Episodic Migrain – Topline data expected to be announced in 2H 2023 – – Topline data from the Company’s Phase 2 trial in preventive…

A Transformation of the Healthcare Experience

Empowering patients, enabling specialists, and driving innovation in the health and wellness industry.

LEARN MORE

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology 

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology  – Positive topline data…

AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia

– Phase 2 trial met primary and secondary endpoints with statistical significance in reducing signs and symptoms associated with cervical dystonia (CD) in adults – – All three dosing arms…

AEON Biopharma Raises $30 Million from Insiders

Brings Total Capital Raised Since December 2021 to $54.5 Million Irvine, Calif., August 3, 2022 – AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on…

AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia

Topline data expected to be announced in the second half of 2022 Newport Beach, Calif., April 11, 2022 – AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical…